Clinical Trial Results:
A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-small-cell lung cancer.
Summary
|
|
EudraCT number |
2005-000317-35 |
Trial protocol |
DE |
Global completion date |
03 Jan 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 May 2016
|
First version publication date |
22 Mar 2015
|
Other versions |
|
Summary report(s) |
1199.10 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.